Gilead: EU approval of Trodelvy and Keytruda for TNBC treatment

Gilead Science (GILD) announced that the Council of Europe had approved the joint use of Trodelvy and Keytruda for the treatment of adults who could not be excised, partially late or transsexual triple-negative breast cancer (TNBC)。